Medtronic (MDT)
96.41
-3.08 (-3.10%)
NYSE · Last Trade: Feb 17th, 6:14 PM EST
Detailed Quote
| Previous Close | 99.49 |
|---|---|
| Open | 95.88 |
| Bid | 96.45 |
| Ask | 96.90 |
| Day's Range | 95.50 - 98.12 |
| 52 Week Range | 79.55 - 106.33 |
| Volume | 17,374,049 |
| Market Cap | 129.57B |
| PE Ratio (TTM) | 25.99 |
| EPS (TTM) | 3.7 |
| Dividend & Yield | 2.840 (2.95%) |
| 1 Month Average Volume | 9,254,965 |
Chart
About Medtronic (MDT)
Medtronic is a global leader in medical technology, focused on developing and providing innovative therapeutic solutions to improve the lives of patients. The company specializes in a wide range of medical devices and therapies, addressing conditions in areas such as diabetes care, cardiovascular health, surgical innovations, and neurological disorders. Medtronic is committed to advancing healthcare through cutting-edge research, collaboration with healthcare providers, and a strong emphasis on patient-centered care, aiming to enhance the quality of life for millions around the world. Read More
News & Press Releases
In a move that signals a massive consolidation in the medical technology sector, Danaher Corporation (NYSE: DHR) announced on February 17, 2026, that it has entered into a definitive agreement to acquire Masimo Corporation (NASDAQ: MASI) for approximately $9.9 billion. The all-cash deal, valued at $180 per share, represents
Via MarketMinute · February 17, 2026
Medtronic beats Q3 sales and earnings estimates, driven by heart and diabetes growth, while reaffirming 2026 outlook.
Via Benzinga · February 17, 2026

Medtronic (MDT) Q3 2026 Earnings Call Transcript
Via The Motley Fool · February 17, 2026
Medtronic (NYSE:MDT) Beats Q3 Earnings Estimates but Stock Dips in Premarketchartmill.com
Via Chartmill · February 17, 2026
Medtronic PLC (NYSE:MDT): A Durable Dividend Stock for Income Investorschartmill.com
Via Chartmill · February 16, 2026
Today’s Date: February 17, 2026 Introduction Medtronic plc (NYSE: MDT) has long been the sleeping giant of the medical technology sector. For years, the Dublin-domiciled powerhouse was viewed by Wall Street as a stable but slow-moving conglomerate, hampered by its own scale and a fragmented organizational structure. However, the narrative has shifted dramatically in early [...]
Via Finterra · February 17, 2026
US stock futures lower. Medtronic, Genuine Parts, Sonoco, Fluor, and Toll Brothers expected to report earnings today.
Via Benzinga · February 17, 2026
On February 16, 2026, the mood surrounding Baxter International (NYSE: BAX) is one of cautious sobriety following a seismic shift in investor confidence. Long regarded as a defensive staple of the healthcare sector, Baxter recently saw its shares plummet by over 16% in a single trading session. This collapse followed a fourth-quarter 2025 earnings report [...]
Via Finterra · February 16, 2026
Dividend-paying stocks tend to greatly outperform non-payers. Here are three promising dividend payers.
Via The Motley Fool · February 16, 2026
Earnings season is starting to slow down now, which may come as a welcome relief for some. However, we do still have some important companies due to report with Walmart, Alibaba, Newmont Mining, Medtronic, Palo Alto Networks, DoorDash and Occidental...
Via Barchart.com · February 16, 2026

Positive earnings pushed Applied Materials and Rivian Automotive higher as better-than-expected inflation data helped steady markets today, Feb. 13, 2026.
Via The Motley Fool · February 13, 2026
Medtronic's Stealth AXiS spine surgery system wins FDA clearance, offering real-time alignment tracking and broader surgical flexibility.
Via Benzinga · February 13, 2026
Becton, Dickinson and Company (NYSE: BDX), widely known as BD, has long been a cornerstone of the global healthcare infrastructure. However, as of February 11, 2026, the company is making headlines not for its traditional stability, but for a radical transformation that has sent shockwaves through the market. Following the official completion of the multi-billion [...]
Via Finterra · February 11, 2026
Waterproof & Reinforced Defense – Pair it with your CGM Blood Glucose Monitoring Sensor or TruSteel Infusion Kit while showering, bathing, exercising or swimming without worry. Protect your CGM sensor from collisions.
Via AB Newswire · February 10, 2026
As of February 9, 2026, the medtech landscape is witnessing a pivotal shift centered around the long-awaited return of robotics to the heart of the operating room. Intuitive Surgical, Inc. (NASDAQ: ISRG), the undisputed pioneer of robotic-assisted surgery (RAS), recently secured a landmark FDA clearance for its next-generation da Vinci 5 platform, specifically for use [...]
Via Finterra · February 9, 2026
Today, February 9, 2026, marks a watershed moment for Becton, Dickinson and Company (NYSE: BDX). The medical technology giant, commonly known as BD, has officially closed its transformative $17.5 billion combination with Waters Corporation (NYSE: WAT), effectively spinning off its Biosciences and Diagnostic Solutions units to create a more streamlined "New BD." Simultaneously, the company [...]
Via Finterra · February 9, 2026
These companies pay very healthy dividends.
Via The Motley Fool · February 8, 2026
Eli Lilly is the leader in the GLP-1 space, but here's another GLP-1 stock and a medical device maker to consider.
Via The Motley Fool · February 7, 2026
In a move that has sent shockwaves through the medical technology sector, Boston Scientific (NYSE:BSX) announced on January 15, 2026, a definitive agreement to acquire Penumbra (NYSE:PEN) for approximately $14.5 billion. The deal represents the largest acquisition for Boston Scientific in over two decades, signaling a transformative
Via MarketMinute · February 5, 2026
February 5, 2026 The medical technology landscape experienced a seismic shift this week as one of its long-standing titans, Boston Scientific (NYSE: BSX), faced a "valuation reset" that has left investors and analysts debating the future of high-growth medtech. For over a decade, Boston Scientific has been the gold standard for consistent execution and category [...]
Via Finterra · February 5, 2026
Today, Feb. 4, 2026, investors are weighing Boston Scientific’s guidance against new deals and its long-term margin path.
Via The Motley Fool · February 4, 2026
AbbVie and Medtronic have a long history of raising their dividends and continue to have healthy free cash flow for further dividend growth.
Via The Motley Fool · February 3, 2026